Treatment-emergent AEs leading to dose interruption/reduction and treatment discontinuation
| Preferred term, unless noted otherwise . | N = 725 n (%) . |
|---|---|
| AE leading to dose interruption/reduction in ≥1% of patients | |
| Any AE | 262 (36.1) |
| Thrombocytopenia | 76 (10.5) |
| Infections and infestations (SOC)∗ | 51 (7.0) |
| Nausea | 15 (2.1) |
| Diarrhea | 14 (1.9) |
| Anemia | 12 (1.7) |
| Neutropenia | 12 (1.7) |
| Asthenia | 11 (1.5) |
| Headache | 11 (1.5) |
| Alanine aminotransferase increased | 9 (1.2) |
| Atrial fibrillation | 8 (1.1) |
| Fatigue | 8 (1.1) |
| Platelet count decreased | 8 (1.1) |
| AE leading to momelotinib discontinuation in ≥1% of patients | |
| Any AE | 229 (31.6) |
| Infections and infestations (SOC)† | 29 (4.0) |
| Thrombocytopenia | 27 (3.7) |
| Peripheral sensory neuropathy | 13 (1.8) |
| Acute myeloid leukemia | 11 (1.5) |
| Disease progression | 11 (1.5) |
| Diarrhea | 8 (1.1) |
| Anemia | 7 (1.0) |
| Splenomegaly | 7 (1.0) |
| Preferred term, unless noted otherwise . | N = 725 n (%) . |
|---|---|
| AE leading to dose interruption/reduction in ≥1% of patients | |
| Any AE | 262 (36.1) |
| Thrombocytopenia | 76 (10.5) |
| Infections and infestations (SOC)∗ | 51 (7.0) |
| Nausea | 15 (2.1) |
| Diarrhea | 14 (1.9) |
| Anemia | 12 (1.7) |
| Neutropenia | 12 (1.7) |
| Asthenia | 11 (1.5) |
| Headache | 11 (1.5) |
| Alanine aminotransferase increased | 9 (1.2) |
| Atrial fibrillation | 8 (1.1) |
| Fatigue | 8 (1.1) |
| Platelet count decreased | 8 (1.1) |
| AE leading to momelotinib discontinuation in ≥1% of patients | |
| Any AE | 229 (31.6) |
| Infections and infestations (SOC)† | 29 (4.0) |
| Thrombocytopenia | 27 (3.7) |
| Peripheral sensory neuropathy | 13 (1.8) |
| Acute myeloid leukemia | 11 (1.5) |
| Disease progression | 11 (1.5) |
| Diarrhea | 8 (1.1) |
| Anemia | 7 (1.0) |
| Splenomegaly | 7 (1.0) |